News|Articles|March 21, 2024

Pharma Pulse 3/21/24: Enhancements and Innovations in Fertility Care, Oprah Delves into GLP-1 Drugs and Obesity-Shaming & more

The latest news for pharma industry insiders.

Embracing the Power of Artificial Intelligence

Fireside chat uncovers ways to leverage this technology in order to boost medication adherence, engagement, and outcomes.

Enhancements and Innovations in Fertility Care

Janet Choi, MD, gives thoughts on innovations in fertility benefits and advocates constant self-evaluation and innovation targeting complete support across reproductive life stages.

Oprah delves into GLP-1 drugs, obesity-shaming

The primetime special from Oprah Winfrey examined the rise of GLP-1 drugs like Ozempic and Mounjaro as well as the need to do away with obesity shaming.

Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

Bayer AG and Thermo Fisher Scientific Inc. announced a collaboration to develop next-generation sequencing-based companion diagnostic assays together. These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

Bristol Myers Squibb on X:

#MEDIA: Announcing positive results from the Phase 3 CheckMate -9DW trial evaluating our immunotherapy combination for the first-line treatment of patients with advanced hepatocellular #carcinoma. https://bit.ly/43qkM16

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.